logo

31.23

31.23 (0.76%)

As of Feb 26, 2024

Immunogen, Inc. [IMGN]

Source: 

Company Overview

We are a clinical-stage biotechnology company focused on developing the next generation of ADCs to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer patients more good days. We call this our commitment to “target a better now.”

CountryUnited States
Headquarterswalthammassachusetts
Phone Number(781)895-0600
Industry
manufacturing
CEOMark J. Enyedy
Websitewww.clinicaltrials.gov